Name: | Perindopril |
---|---|
PubChem Compound ID: | 107807 |
Description: | An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure. |
Molecular formula: | C19H32N2O5 |
Molecular weight: | 368.468 g/mol |
Synonyms: |
Aceon; SED-9490; 1H-Indole-2-carboxylic acid, 1-((2S)-2-(((1S)-1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S,3aS,7aS)-; DW-7950; Spectrum2_001108; Spectrum4_000775; Coverex; McN-A-2833; Coverene Cor; Spectrum_001948.
show more » |
Name: | Perindopril |
---|---|
Name (isomeric): | DB00790 |
Drug Type: | small molecule |
Description: | An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure. |
Synonyms: |
Perindopril Erbumine
|
Brand: | Aceon, Coversyl |
Brand name mixture: | Preterax(perindopril erbumine + indapamide), Coversyl Plus(perindopril erbumine + indapamide) |
Category: | Angiotensin-converting Enzyme Inhibitors, Antihypertensive Agents |
CAS number: | 107133-36-8 |
Indication: | For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. |
---|---|
Pharmacology: |
Perindopril is a nonsulfhydryl prodrug that is metabolized via first pass effect (62%) and systemic hydrolysis (38%) to perindoprilat, its active metabolite, following oral administration. Perindoprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyt...
show more » |
Mechanism of Action: |
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, w...
show more » |
Absorption: | Rapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%. |
Protein binding: | Perindoprilat, 10-20% bound to plasma proteins |
Biotransformation: | Extensively metabolized, with only 4-12% of the dose recovered in urine following oral administration. Six metabolites have been identified: perindoprilat, perindopril glucuronide, perindoprilat glucuronide, a perindopril lactam, and two perindoprilat lactams. Only perindoprilat is pharmacologically active. Peridoprilat and perindoprilat glucuronide are the two main circulating metabolites. |
Route of elimination: | Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine. |
Half Life: | Perindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites. |
Clearance: | 219 - 362 mL/min [oral administration] |
Toxicity: | The most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|